iRadimed
IRMD
54 hedge funds and large institutions have $122M invested in iRadimed in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
14% more capital invested
Capital invested by funds: $107M → $122M (+$14.8M)
0.11% more ownership
Funds ownership: 38.3% → 38.42% (+0.11%)
0% more funds holding
Funds holding: 54 → 54 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
35% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.25M |
| 2 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
+$2.34M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$629K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$452K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$2.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.79M |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$779K |
| 4 |
Morgan Stanley
New York
|
-$639K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$412K |
IRMD Hedge Fund Activity: Q1 2021 in Review
54 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q1 2021, worth a combined $122M — up 14% from $107M a quarter earlier.
Fund positioning in IRMD was balanced in Q1 2021: 6 funds opened new positions, 6 closed out, 15 added to existing stakes and 23 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $4.25M. The largest seller was Russell Investments Group, cutting an estimated $2.15M.
- 54 institutional investors held iRadimed (IRMD) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $122M of iRadimed stock for Q1 2021, up 14% quarter-over-quarter.
- 6 funds opened new iRadimed positions in Q1 2021 and 6 closed out, a net change of 0 holders.
- The largest iRadimed buyer in Q1 2021 was Soleus Capital Management, an estimated $4.25M added.
- The largest iRadimed seller in Q1 2021 was Russell Investments Group, an estimated $2.15M sold.
Based on aggregated 13F filings for Q1 2021.